Instructions for use

The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document.

Coverage determinations in each specific instance require consideration of:
1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

©Copyright 2017 eviCore healthcare
### CMM-209~Regional Sympathetic Blocks

<table>
<thead>
<tr>
<th>CMM-209</th>
<th>Regional Sympathetic Blocks</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>209.1</td>
<td>Definitions</td>
<td>3</td>
</tr>
<tr>
<td>209.2</td>
<td>General Guidelines</td>
<td>4</td>
</tr>
<tr>
<td>209.3</td>
<td>Indications</td>
<td>4</td>
</tr>
<tr>
<td>209.4</td>
<td>Non-Indications</td>
<td>4</td>
</tr>
<tr>
<td>209.5</td>
<td>Procedure (CPT®) Codes</td>
<td>5</td>
</tr>
<tr>
<td>209.6</td>
<td>References</td>
<td>5</td>
</tr>
</tbody>
</table>
CMM-209.1 Definitions

Regional sympathetic blocks (Stellate Ganglion Blocks and Lumbar Sympathetic Blocks) refer to the injection of local anesthetic along the sympathetic ganglia of the anterolateral aspect of the spinal column under fluoroscopy to reduce sympathetic nervous system activity related to the affected limb. A diagnostic regional sympathetic block is considered positive when there is significant reduction in pain and improvement in function for the duration of the local anesthetic used.

Complex Regional Pain Syndrome (CRPS) is defined by the International Association for the Study of Pain (IASP) as a variety of painful conditions following injury which appear regionally having a distal predominance of abnormal findings, exceeding in both magnitude and duration the expected clinical course of the inciting event and often resulting in significant impairment of motor function, and showing variable progression over time. In addition to injury, CRPS can also occur as a result of various medical disorders or illnesses. The diagnostic criteria for CRPS are as follows:

- Continuing pain that is disproportionate to any inciting event
- Must report at least one (1) of the symptoms in the following categories:
  - Sensory: reports of hyperesthesia
  - Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry
  - Sudomotor/edema: reports of edema and/or sweating changes and/or sweating asymmetry
  - Motor/trophic: reports of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).
- Must display at least one (1) of the signs in the following categories:
  - Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch)
  - Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or asymmetry
  - Sudomotor/edema: evidence of edema and/or sweating changes and/or sweating asymmetry
  - Motor/trophic: evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).
CMM-209.2 General Guidelines

Regional sympathetic blocks should be performed using fluoroscopy.

✓ Due to insufficient evidence that regional sympathetic blocks (Stellate Ganglion Blocks and Lumbar Sympathetic Chain Blocks) performed as an isolated treatment alter the long term outcome of CRPS, all regional sympathetic blocks in recalcitrant cases of CRPS should be performed with the intent of facilitating involvement and advancement in an active rehabilitation/functional restoration program.

CMM-209.3 Indications

The performance of an initial diagnostic regional sympathetic block is considered medically necessary to establish the presence or absence of sympathetically mediated complex regional pain syndrome. A positive response is defined as a significant reduction in pain and improvement in function for the duration of the local anesthetic used.

Following a successful initial diagnostic block, three (3) additional therapeutic regional sympathetic blocks, performed within the first two (2) weeks of the initial block, may be considered medically necessary to diagnose the individual’s pain and obtain a therapeutic response.

Additional therapeutic regional sympathetic blocks, up to a maximum of six (6) total blocks, which should be performed at a one (1) time per week frequency, is considered medically necessary when provided as part of a comprehensive pain management program and ALL of the following criteria are met:

- decreased use of pain medication
- increased functional ability (e.g., increased range of motion, strength, and use of the extremity in activities of daily living)
- increased tolerance to touch (e.g., decreased allodynia)
- ongoing participation in an active rehabilitation program.

CMM - 209.4 Non-Indications

Regional sympathetic blocks are considered not medically necessary for each of the following conditions:

- when the individual is not capable of participating or is not involved in an
ongoing, active rehabilitation program
- without the use of fluoroscopic guidance
- as a repeat therapeutic block when there is no decrease in use of pain medication, increase in functional ability, and increase of tolerance to touch
- if following the initial block there is no significant reduction in pain and improvement in function for the duration of local anesthetic

**CMM-209.5 Procedure (CPT®) Codes**

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Code Description/Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>64510</td>
<td>Injection, anesthetic agent; stellate ganglion (cervical sympathetic)</td>
</tr>
<tr>
<td>64520</td>
<td>Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)</td>
</tr>
</tbody>
</table>

This guideline relates to the CPT® code set below. Codes are displayed for informational purposes only. Any given code’s inclusion on this list does not necessarily indicate prior authorization is needed.

This list may not be all inclusive and is not intended to be used for coding/billing purposes. The final determination of reimbursement for services is the decision of the health plan and is based on the individual’s policy or benefit entitlement structure as well as claims processing rules.

**CMM-209.6 References**


